Search results
Results from the WOW.Com Content Network
Timing is everything for many things in life — including when to take medication like metformin, sold under the brand names Glucophage, Fortamet, Riomet, and Glumetza.
Metformin was approved in Canada in 1972, [6] but did not receive approval by the U.S. Food and Drug Administration (FDA) for type 2 diabetes until 1994. [170] Produced under license by Bristol-Myers Squibb, Glucophage was the first branded formulation of metformin to be marketed in the U.S., beginning on 3 March 1995. [171]
The Pharmaceutical Price Regulation Scheme (PPRS) is the mechanism used by the UK Department of Health to ensure that the NHS has access to good quality branded medicines at reasonable prices. It involves a non-contractual agreement between the UK Department of Health and The Association of the British Pharmaceutical Industry (ABPI). The scheme ...
Another small study on people without diabetes who were overweight or had obesity found that those taking metformin lost between 5.6 and 6.5 percent of their body weight. In contrast, the control ...
Vildagliptin is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes as monotherapy in people in whom metformin is inappropriate due to contraindications or intolerance; and in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycemic control.
Whether use in pregnancy or breastfeeding is safe is unclear. [10] It is in the dipeptidyl peptidase-4 (DPP-4) inhibitor class and works by increasing the production of insulin and decreasing the production of glucagon by the pancreas. [8] Sitagliptin was developed by Merck & Co. and approved for medical use in the United States in 2006. [8]
It was approved for use in the European Union in November 2007, [4] and the approval was updated in 2008. [5] [6] [7] It combines 50 mg vildagliptin with either 500, 850, or 1000 mg metformin. [8] The most common side effects include nausea (feeling sick), vomiting, diarrhea, abdominal (tummy) pain and loss of appetite. [4] [6] [7]
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [5] [6]In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people ...